{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7343","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.4","value":"13.1"},{"groupId":"OG001","spread":"7.8","value":"11.7"},{"comment":"Only one data point, hence standard deviation could not be calculated","groupId":"OG002","spread":"NA","value":"5.4"},{"comment":"Only one data point, hence standard deviation could not be calculated","groupId":"OG003","spread":"NA","value":"17.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Primary Objective 1: To assess whether the novel MR protocol and exploratory bone biomarkers can improve quantification of tumour burden in patients with new or relapsed myeloma at baseline assessment, compared to paraprotein levels alone.\n\nParticipants' baseline novel MR scan was analysed by an expert radiologist, and pattern of disease was qualitatively classified using the MY-RADS (Myeloma Response Assessment and Diagnosis System) imaging recommendations, described in Figure 2 by Messiou et. al. \\[1\\].\n\nThis particular section analysed whether standard clinical correlate of tumour burden (serum paraprotein) differed by radiological pattern of disease (e.g., normal, focal, diffuse).\n\n\\[1\\] Messiou, Christina, et al. \"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS).\" Radiology 291.1 (2019): 5-13.","dispersionType":"Standard Deviation","groups":[{"description":"MY-RADS disease pattern classification, as assessed by an expert MSK Radiologist, on baseline scans","id":"OG000","title":"MY-RADS: Normal"},{"description":"MY-RADS disease pattern classification, as assessed by an expert MSK Radiologist, on baseline scans","id":"OG001","title":"MY-RADS: Focal"},{"description":"MY-RADS disease pattern classification, as assessed by an expert MSK Radiologist, on baseline scans","id":"OG002","title":"MY-RADS: Micronodular"},{"description":"MY-RADS disease pattern classification, as assessed by an expert MSK Radiologist, on baseline scans","id":"OG003","title":"MY-RADS: Not Determined"}],"paramType":"MEAN","populationDescription":"Population is all participants who had a novel MR scan at baseline with: i) available MY-RADS pattern of disease assessment; ii) available baseline serum paraprotein.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Primary Outcome 1: Quantifying Tumour Burden [Correlations With Myeloma Response Assessment and Diagnosis System (MY-RADS) Pattern of Disease]","type":"PRIMARY","unitOfMeasure":"grams per liter (g/L)"}